Patents by Inventor Michael Douglas Moore

Michael Douglas Moore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES
    Publication number: 20230364073
    Abstract: Pharmaceutical compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) in Form I and a solid dispersion comprising substantially amorphous N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Compound 2), methods of treating, lessening the severity of, or symptomatically treating CFTR mediated diseases, such as cystic fibrosis, methods of manufacturing, methods of administering, and kits thereof are disclosed.
    Type: Application
    Filed: December 30, 2022
    Publication date: November 16, 2023
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Marinus Jacobus VERWIJS, Radhika KARKARE, Michael Douglas MOORE
  • PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES
    Publication number: 20200338063
    Abstract: Pharmaceutical compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) in Form I and a solid dispersion comprising substantially amorphous N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Compound 2), methods of treating, lessening the severity of, or symptomatically treating CFTR mediated diseases, such as cystic fibrosis, methods of manufacturing, methods of administering, and kits thereof are disclosed.
    Type: Application
    Filed: December 20, 2019
    Publication date: October 29, 2020
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Marinus Jacobus VERWIJS, Radhika KARKARE, Michael Douglas MOORE
  • Pharmaceutical Compositions for the Treatment of CFTR Mediated Diseases
    Publication number: 20160324846
    Abstract: Pharmaceutical compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) in Form I and a solid dispersion comprising substantially amorphous N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Compound 2), methods of treating, lessening the severity of, or symptomatically treating CFTR mediated diseases, such as cystic fibrosis, methods of manufacturing, methods of administering, and kits thereof are disclosed.
    Type: Application
    Filed: May 11, 2016
    Publication date: November 10, 2016
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Marinus Jacobus Verwijs, Radhika Karkare, Michael Douglas Moore
  • Pharmaceutical Compositions for the Treatment of CFTR Mediated Diseases
    Publication number: 20140163068
    Abstract: Pharmaceutical compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) in Form I and a solid dispersion comprising substantially amorphous N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Compound 2), methods of treating, lessening the severity of, or symptomatically treating CFTR mediated diseases, such as cystic fibrosis, methods of manufacturing, methods of administering, and kits thereof are disclosed.
    Type: Application
    Filed: November 1, 2013
    Publication date: June 12, 2014
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Marinus Jacobus Verwijs, Radhika Karkare, Michael Douglas Moore